Press Release: ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY | Globe NewsWire News Distribution Service

Choose a language:

Globe NewsWire News Distribution Service

Details: Written by Globe NewsWire Press Releases; Category: Globe NewsWire News Distribution Service; Published: 28 August 2026; Created: 28 August 2026; Last Updated: 28 August 2026

NEW YORK, Aug. 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”), of the important October 5, 2026 lead plaintiff deadline.

Posted: 2026-08-28 21:50:00

Get Full News Story On GlobeNewsWire Press Release Service

More News From This Category
Press Release: AVEX Class Action Reminder: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the AEVEX Corp. Securities Class Action
Fri, 28 Aug 2026 19:08:22 +0000

Robbins LLP is Investigating Whether AEVEX Corp. Concealed a Pre-Arranged Plan to Override a Commitment by Madison Requiring a 180-day Lock-Up

Press Release: Kaplan Fox & Kilsheimer LLP Announces the Filing of a Securities Class Action against GoDaddy Inc. (NYSE: GDDY) – Contact the Firm Before October 20, 2026 for a Leadership Role
Fri, 28 Aug 2026 16:08:13 +0000

NYSE:GDDY ALERT: If you are an investor in GoDaddy Inc. and have suffered losses, contact Kaplan Fox to learn about eligibility.

Press Release: Sustainable Innovation & Health Dividend Fund Normal Course Issuer Bid
Fri, 28 Aug 2026 13:08:20 +0000

TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Sustainable Innovation & Health Dividend Fund (the “Fund”) (TSX: SIH.UN) announced that it has filed a notice with the Toronto Stock Exchange (the “TSX”) and received its approval to make a normal course issuer bid (“NCIB”). Purchases pursuant to the NCIB will be made in the open market…

Press Release: Genetic Testing Market Size to Surge to USD 62.61 Billion by 2035 – SNS Insider
Fri, 28 Aug 2026 10:08:08 +0000

U.S. Genetic Testing Market to Reach USD 16.92 Billion and Europe USD 18.78 Billion by 2035, Driven by NGS, Liquid Biopsy and Personalized Medicine U.S. Genetic Testing Market to Reach USD 16.92 Billion and Europe USD 18.78 Billion by 2035, Driven by NGS, Liquid Biopsy and Personalized Medicine

Related Bing News Results